Fertility-sparing surgery of malignant transformation arising from mature cystic teratoma of the ovary

Nobuhisa Yoshikawa1,*, Toshiya Teshigawara1,*, Yoshiki Ikeda1, Kimihiro Nishino1, Jun Sakata1, Fumi Utsumi1, Kaoru Niimi1, Ryuichiro Sekiya2, Shiro Suzuki1, Michiyasu Kawai3, Kiyosumi Shibata2, Fumitaka Kikkawa1 and Hiroaki Kajiyama1

1Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
2Department of Obstetrics and Gynecology, Fujita Health University Banbuntane Hotokukai Hospital, Nagoya, Japan
3Department of Obstetrics and Gynecology, Toyohashi Municipal Hospital, Toyohashi, Japan
*These authors have contributed equally to this work
Correspondence to: Nobuhisa Yoshikawa, email: n-yoshikawa@med.nagoya-u.ac.jp
Hiroaki Kajiyama, email: kajiyama@med.nagoya-u.ac.jp

Keywords: malignant transformation; mature cystic teratoma; fertility-sparing surgery; oncological outcome; reproductive outcome

Abbreviations: MT-MCT (malignant transformation arising from mature cystic teratoma of the ovary), FSS (fertility-sparing surgery), OS (overall survival), DFS (disease-free survival), EOC (epithelial ovarian cancer)

ABSTRACT

Background: The purpose of this study was to evaluate the long-term clinical outcome of young women with malignant transformation arising from mature cystic teratoma of the ovary (MT-MCT) by comparing radical surgery and fertility-sparing surgery (FSS).

Patients and methods: All patients treated with radical surgery or FSS for MT-MCT in multiple institutions were registered in this analysis. Univariate and multivariate analyses were performed to evaluate clinical outcome, including overall survival (OS) and disease-free survival (DFS).

Results: From 1986 to 2016, 62 patients with MT-MCT were treated in our group. The median follow-up period was 38.0 (2.0-227.9) months, and the median age was 54 (17-82) years old. Multivariate analysis revealed that only advanced stage was significantly correlated with poorer prognosis of patients [hazard ratio (HR) for death: 6.58, 95% confidence interval (CI): 1.82–24.78, P = 0.0048; HR for recurrence: 5.59, 95% CI: 1.52–21.83, P = 0.01]. Of a total of 13 women with stage I-II disease at less than 45 years old, 7 were treated with FSS, and there was no recurrence except for one woman with stage II MT-MCT. There was no significant difference in long-term oncological outcome between radical surgery and FSS.

Conclusion: FSS may be indicated for patients with stage I MT-MCT, who hope to preserve fertility, as no relapse was found after FSS.

INTRODUCTION

Usually, fertility-sparing surgery (FSS) has been acceptably chosen for young patients with an ovarian-confined / capsulated / well-differentiated epithelial ovarian cancer (EOC), as well as those with borderline, germ cell, and stromal tumor. Previous studies reported FSS as an alternative therapy to radical surgery in selected patients of child-bearing age, when the oncological outcome of patients treated with FSS was determined to be equivalent to that of patients treated with radical surgery [1–6]. However, evidence supporting the safety and effectiveness of conservative surgery is limited, and a standard indication for FSS remains controversial even for EOC, because randomized clinical trials are difficult to conduct due to ethical issues.
Mature cystic teratoma (MCT) is a common asymptomatic disease in women of child-bearing age, comprising up to a quarter of all ovarian tumors, with an incidence of 1.2-14.2 cases per 100000 per year [7–10]. MCT normally contains mature tissues from all three germ-cell layers (ectoderm, mesoderm and endoderm). It has been reported that malignant transformation of MCT (MT-MCT) usually occurs only in approximately 1-3% of MCT cases [9]. The most common malignant histological type of MT-MCT is squamous cell carcinoma (SCC) originating from ectodermal tissue, which accounts for 80-90%, but adenocarcinomas, carcinoid tumors and melanomas have also been reported infrequently [9, 11–13]. Although MT-MCT is normally diagnosed at menopausal age, our colleagues reported at least one fourth of MT-MCT actually occurs in reproductive-age women [14]. Due to its rarity, MT-MCT is not even independently categorized as a type of histology into the National Comprehensive Cancer Network Guidelines 2017. To our best knowledge, there has been no study assessing the applicability of FSS for MT-MCT.

This study was aimed to overview the oncologic outcome patients in our experience and explore the eligibility of FSS for MT-MCT. An insight into the valid management strategies for MT-MCT in child-bearing age was proposed.

RESULTS

From 1986 to 2016, a total of 62 patients with MT-MCT were registered to this study. The clinicopathological characteristics of these patients are summarized in Table 1. The median follow-up time and the median age of patients were 38.0 (2.0-227.9) months and 54 (17-82) years old. Of a total of 62 patients, 38 patients had stage I disease, 5 had stage II disease, 17 had stage III, and 2 had stage IV, respectively. A total of 17 (27.4%) patients were treated with conservative surgery instead of radical surgery. Squamous cell carcinoma accounted for more than 90% of our cases. We first overviewed oncologic outcome of patients in our experience. Kaplan-Meier curves of OS and DFS, demonstrating demonstrated both 5-year OS and DFS of our cases. We first overviewed oncologic outcome of patients in our experience and explore the eligibility of FSS for MT-MCT.

We subsequently explore the possibility of FSS in young patients with MT-MCT. The clinicopathological features of patients with early stage disease among group A, B, and C are summarized in Table 3. Of seven patients in group A, five patients underwent unilateral salpingooophorectomy, and the other two patients received unilateral cystectomy. We selected FSS for the patient with stage II MT-MCT because they wished to preserve fertility regardless of our recommendation for radical surgery, which resulted in recurrence. Three patients treated with FSS underwent adjuvant chemotherapy. The clinical characteristics excluding surgical procedures were not statistically different among the three groups.

With regard to obstetrical outcome after FSS, two patients gave birth to healthy children. One patient became pregnant and gave birth to a healthy child after FSS, and the other patient underwent unilateral cystectomy for MT-MCT at 16 weeks pregnant, and then had a baby by cesarean section.

All 25 MT-MCT patients treated with conservative surgery listed in Table 4 were derived from previous representative reports and our current study [15–24]. The median age of these patients was 31 years old (19-41). Only one patient with stage II disease in our study relapsed (4%) and died due to disease progression. Except for this patient, the other 24 patients had stage I disease. Eight out of 24 patients (33.3%) with stage I MT-MCT received adjuvant chemotherapy following FSS, including paclitaxel and cisplatin. With respect to surgical procedure, unilateral oophorectomy and lymphadenectomy were mainly performed as FSS.

DISCUSSION

Preservation of reproductive function is strongly desired by patients with ovarian malignancy at child-bearing age. Previous reports analyzing the clinical outcomes of women who received the surgical procedure have revealed the possibility of preserving fertility in early stage EOC [2, 25]. Regarding MT-MCT, there is currently no study evaluating eligibility for FSS or proposing criteria for FSS. Our current study is the largest case series study to evaluate prognostic factors affecting long-term clinical outcome of patients with MT-MCT, and to propose recommended criteria for FSS for MT-MCT.

Preoperative diagnosis of MT-MCT is difficult, especially in early stages, thus MT-MCT is usually diagnosed by postoperative histopathological examination. Moreover, like other ovarian malignancies, it is reported that the prognosis of this disease depends on the stage at
Table 1: Patient characteristics

| Characteristic                  | n (%) |
|---------------------------------|-------|
| **Age, years**                  |       |
| median age (range)              | 54 (17-82) |
| ≥60                              | 25 (40.3) |
| 45-59                           | 17 (27.4) |
| <45                             | 20 (32.3) |
| **Stage**                       |       |
| I                               | 38 (61.3) |
| IA                              | 22 |
| IC                              | 16 |
| II                              | 5 (8.1) |
| IIA                             | 1 |
| IIB                             | 2 |
| IIC                             | 2 |
| III                             | 17 (27.4) |
| IIIB                            | 7 |
| IIIC                            | 10 |
| IV                              | 2 (3.2) |
| **Surgical Procedures**         |       |
| Radical surgery                 | 45 (72.6) |
| Complete surgery*               | 15 |
| Incomplete surgery**            | 30 |
| Conservative surgery            | 17 (27.4) |
| **Residual tumor**              |       |
| Yes                             | 53 (85.5) |
| No                              | 9 (14.5) |
| **Histology**                   |       |
| Squamous cell carcinoma         | 57 (91.9) |
| Adenocarcinoma                  | 3 (4.8) |
| Adenosquamous carcinoma         | 1 (1.6) |
| Malignant melanoma              | 1 (1.6) |
| **SCC (ng/dL)**                 |       |
| < 2                             | 9 (14.5) |
| ≥ 2                             | 31 (50.0) |
| Unknown                         | 22 (35.5) |
| **CA125 (U/mL)**                |       |
| < 100                           | 45 (72.6) |
| ≥ 100                           | 15 (24.2) |

(Continued)
A previous study on 37 patients with MT-MCT reported that the 5-year survival rates was 94.7% for stage I, 80.0% for stage II and 0% for stage III and stage IV, indicating that patients with the disease in FIGO stage I have a relatively good prognosis [26]. Indeed, the 5-year OS of our patients with early stage MT-MCT was more favorable than that of patients with advanced stage MT-MCT in the total population. The FIGO stage at diagnosis was the only determinant of survival outcome according to our multivariate analysis. We suggest that conservative surgery may acceptable only for patients with early stage disease, and should not be applied to patients with advanced stage, although it is difficult to correlate the prognosis of these patients with surgical procedures.

Compared with previous reports, 5-year OS and DFS of stage I MT-MCT in this study were likely to be equivalent with those of stage I EOC [3, 9, 26, 27]. On the other hand, the prognosis of stage II MT-MCT was poorer than that of stage I disease, as in previous stage II MT-MCT.

Optimal surgical procedures for MT-MCT are undefined, compared with those for EOC. According to the National Comprehensive Cancer Network Guidelines 2017, FSS including USO preserving the uterus and bilateral salpingo-oophorectomy with peritoneal staging and lymphadenectomy. Incomplete surgery was defined as completion of total hysterectomy and bilateral salpingo-oophorectomy.

### Table 2: Uni- and multivariate analyses of clinicopathologic parameters in relation to OS and DFS of patients

| Variable                              | Univariate          | Multivariate       |
|---------------------------------------|----------------------|--------------------|
|                                       | HR                  | 95%CI              | P-value | HR                 | 95%CI              | P-value |
| Overall survival                      |                      |                    |         |                    |                    |         |
| Age (≥45 versus <45)                  | 0.68                 | 0.28-1.75          | 0.41    | 0.53               | 0.19-1.49          | 0.22    |
| Stage (III-IV versus I-II)            | 6.14                 | 2.50-15.9          | <0.0001 | 6.58               | 1.82-24.78         | 0.0048  |
| Surgical procedures (Conservative versus Radical) | 0.41 | 0.10-1.24          | 0.12    | 0.75               | 0.13-3.30          | 0.71    |
| Residual tumor (Yes versus No)        | 3.74                 | 1.32-9.36          | 0.02    | 0.76               | 0.21-2.74          | 0.67    |
| SCC (≥2.0 versus <2.0)(ng/dL)         | 2.20                 | 0.59-14.27         | 0.26    | 1.30               | 0.25-10.50         | 0.77    |
| ≥100 versus <100)(U/mL)               | 1.57                 | 0.59-3.84          | 0.35    | 1.25               | 0.44-3.33          | 0.66    |
| Chemotherapy (Yes versus No)          | 205                  | 0.73-7.24          | 0.18    | 0.79               | 0.23-3.13          | 0.72    |
| Disease-free survival                 |                      |                    |         |                    |                    |         |
| Age (≥45 versus <45)                  | 0.69                 | 0.29-1.78          | 0.43    | 0.57               | 0.20-1.63          | 0.29    |
| Stage (III-IV versus I-II)            | 5.43                 | 2.22-14.01         | 0.0002  | 5.59               | 1.52-21.83         | 0.01    |
| Surgical procedures (Conservative versus Radical) | 0.43 | 0.10-1.30          | 0.14    | 0.86               | 0.16-3.75          | 0.84    |
| Residual tumor (Yes versus No)        | 3.50                 | 1.23-8.76          | 0.02    | 0.81               | 0.23-2.93          | 0.75    |
| SCC (≥2.0 versus <2.0)(ng/dL)         | 1.97                 | 0.53-12.73         | 0.34    | 0.99               | 0.20-7.41          | 0.99    |
| ≥100 versus <100)(U/mL)               | 1.69                 | 0.63-4.13          | 0.28    | 1.27               | 0.45-3.30          | 0.64    |
| Chemotherapy (Yes versus No)          | 2.09                 | 0.32-12.03         | 0.36    | 0.86               | 0.25-3.42          | 0.82    |
contralateral ovary may be considered for patients with apparent early-stage disease and/or good-risk tumors, including malignant germ cell tumors, who hope to preserve fertility, whereas complete staging surgery is recommended for patients not desiring fertility preservation [28]. However, there are no criteria regarding FSS for MT-MCT. To our best knowledge, there are only a few reports regarding FSS for patients of reproductive age with MT-MCT who desire future fertility. Gainford et al. reported that FSS may be a reasonable choice in selected patients with stage I disease, based on their experiences [18]. However, we think that the number of patients are too small-scale to draw a reliable conclusion with respect to validity of FSS. In this study, we presented the clinical outcomes of a total of 62 patients with MT-MCT, and our results demonstrated no correlation between prognosis and surgical procedure by both univariate and multivariate analyses. Furthermore, in our study, not

Table 3: Clinicopathological features of early stage MT-MCT among group A, B, and C

|                                | Group A (n=7) | Group B (n=6) | Group C (n=30) | P-value |
|--------------------------------|--------------|--------------|---------------|---------|
| Stage                          |              |              |               | 0.2965  |
| I                              | 6            | 5            | 27            |         |
| IA                             | 4            | 2            | 16            |         |
| IC                             | 2            | 3            | 11            |         |
| II                             | 1            | 1            | 3             |         |
| IIA                            | 1            | 0            | 0             |         |
| IIB                            | 0            | 0            | 2             |         |
| IIC                            | 0            | 1            | 1             |         |
| Surgical procedures            |              |              |               | 0.0032  |
| Radical surgery                | 0            | 6            | 21            |         |
| Complete surgery               | 0            | 4            | 7             |         |
| Incomplete surgery             | 0            | 2            | 14            |         |
| Conservative surgery           | 7            | 0            | 9             |         |
| Histology                      |              |              |               | 0.8416  |
| Squamous cell carcinoma        | 6            | 6            | 28            |         |
| Adenocarcinoma                 | 0            | 0            | 1             |         |
| Adenosquamous carcinoma        | 1            | 0            | 1             |         |
| Malignant melanoma             | 0            | 0            | 0             |         |
| SCC (ng/dL)                    |              |              |               | 0.8818  |
| < 2                            | 2            | 1            | 5             |         |
| ≥ 2                            | 2            | 3            | 15            |         |
| Unknown                        | 3            | 2            | 10            |         |
| CA125 (U/mL)                   |              |              |               | 0.35    |
| < 100                          | 6            | 5            | 21            |         |
| ≥ 100                          | 1            | 0            | 8             |         |
| Unknown                        | 0            | 1            | 1             |         |
| Adjuvant Chemotherapy          |              |              |               | 0.8475  |
| Yes                            | 3            | 4            | 16            |         |
| No                             | 3            | 2            | 12            |         |
| Unknown                        | 1            | 0            | 2             |         |
only unilateral salpingo-oophorectomy but unilateral
cystectomy was performed as FSS for stage I disease,
with no relapse. MT-MCT is frequently diagnosed at
postoperative histopathological examination even if the
preoperative diagnosis was benign. Our results suggest
that patients treated with unilateral cystectomy may not
need to undergo additional radical surgery following
primary surgery.

According to the comparison of the younger
age group (≤45) with the older age group (>45) in the
univariate analysis, the survival differences in OS and
DFS were not significant. Additionally, in the younger
age group, 5-year OS and DFS of patients undergoing
FSS were likely to be equivalent with those of patients
who underwent radical surgery. Limited to stage I disease,
there was no recurrence in both patients treated with FSS
and in patients treated with radical surgery. However, we
observed recurrence following FSS in the patient with
stage II MT-MCT due to her hope to preserve fertility. Our
results suggest that FSS may be an acceptable choice for
patients with stage I MT-MCT but not for those with stage
II disease.

As summarized in Table 4, there was no relapse
in a total of 25 patients with stage I disease treated with
FSS, therefore, conservative surgery for patients with
MT-MCT may be applicable at least for stage I MT-MCT.
Although the significance of adjuvant chemotherapy
following conservative surgery is not well understood,
approximately one-third of patients with stage I MT-
MCT received adjuvant chemotherapy following FSS.
To maximize fertility preservation, conservative surgery
followed by adjuvant chemotherapy may be a reasonable
choice. However, we should keep in mind the possibility
of the publication bias. Namely, it is unlikely that any
surgeon would have report a case in which the patient
have recurred and/or died from disease. It is possible that
patients who have favorable clinical outcome tends to be
reported particularly in a case study.

The limitations of the current report are those associated
with any retrospective study, containing a possibility of
selection bias, and treatment heterogeneity. Indeed, because
our cases were accumulated from multiple institutions over
a long time, the treatment protocol for MT-MCT, including
the salvage chemotherapy, was not necessarily consistent.
Moreover, the most weakness of our current study was based
on small-scale patient number due to the fact that experience
of patients with MT-MCT was extremely rare. Particularly, in
multivariable analysis, including a variety of clinicopathologic

![Figure 1: Kaplan-Meier estimated OS of early stage MT-MCT patients divided into three groups: group A, patients who underwent FSS under 45 years old; group B, patients who underwent radical surgery under 45 years old; group C, patients over 46 years old.](attachment:image.png)
indicators, the significance of the residual tumor disappeared as an independent prognostic factor (HR: 0.76, P= 0.67, 95% CI: 0.21-2.74). Probably, because the stage and residual tumor were strongly correlated with each other, we speculate that the “multicolinearity” might be observed. We also think that it might be related to the small-scale sample number as type II error. In this context, this investigation is a hypothesis-generating study on the application and expectable effect of FSS in young women with MT-MCT. We would like to reevaluate the results of the current examination in other future study, accumulating more and more patients with MT-MCT.

In conclusion, although the criteria for FSS for early stage MT-MCT is not well established, FSS may be an alternative to radical surgery for women of child-bearing age.

Table 4: Summary of clinical outcomes and fertility results of MT-MCT patients treated conservatively in our current study and previous reports

| Case ID | Author       | Age | Stage | Primary Surgery | Histology | Adjuvant Chemotherapy | Chemotherapy (course) | Status | Overall Survival (months) | Pregnancy outcome |
|---------|--------------|-----|-------|-----------------|-----------|------------------------|-----------------------|--------|--------------------------|------------------|
| 1       | Current report | 41  | IA    | RSO             | SCC       | No                     |                       | NED    | 226                      | -                |
| 2       |              | 30  | IA    | RSO             | SCC       | No                     |                       | NED    | 131                      | 1 (NVD)          |
| 3       |              | 33  | IA    | RSO + App       | SCC       | Yes                    | PTX + CBDCA (3)       | NED    | 60                       | -                |
| 4       |              | 40  | IC    | RSO             | SCC       | No                     |                       | NED    | 24                       | -                |
| 5       |              | 38  | IA    | left cystectomy | SCC       | Yes                    | PTX + CBDCA (3)       | NED    | 10                       | -                |
| 6       |              | 31  | IIA   | RSO + left cystectomy + OM | SCC | Yes | CDDP + 5FU (1) GEM + CBDCA (4) + Bev (3) | DOD | 10 | - |
| 7       |              | 30  | IC    | right cystectomy | AC | NA |                       |                       | NED    | 11 | 1 (CS) |
| 8       | Tseng        | 31  | IA    | USO             | SCC       | -                      | -                     | NED    | 51 | NA |
| 9       |              | 21  | IA    | USO             | SCC       | -                      | -                     | NED    | 105 | NA |
| 10      |              | 22  | IA    | LSO             | SCC       | -                      | -                     | NED    | 121 | NA |
| 11      |              | 34  | IA    | USO             | SCC       | -                      | -                     | NED    | 91 | NA |
| 12      | Rim          | 19  | IA    | LSO             | SCC       | -                      | -                     | NED    | 5 | NA |
| 13      |              | 36  | IA    | LSO             | SCC       | -                      | -                     | NED    | 20 | NA |
| 14      | Arioz        | 31  | IIA   | USO + OM + PLND + PALND + App | SCC | Yes | PTX + CDDP (6) | NED | 6 | NA |
| 15      | Gainford     | 31  | IA    | USO             | SCC       | Yes                    | CDDP + ETP (5)        | NED    | 108 | NA |
| 16      |              | 21  | IA    | USO             | SCC       | -                      | -                     | NED    | 12 | NA |
| 17      |              | 27  | IA    | USO             | SCC       | -                      | -                     | NED    | 48 | NA |
| 18      | Sakuma       | 36  | IA    | LSO             | SCC       | -                      | -                     | NED    | 72 | NA |
| 19      |              | 21  | IA    | RSO             | SCC       | -                      | -                     | NED    | 37 | 1 (NVD) |
| 20      | Budiman      | 32  | IA    | RSO             | SCC       | Yes                    | BEP (6)               | NED    | 104 | NA |
| 21      | Chiang       | 30  | -     | LSO + right cystectomy | SCC | - | - | NED | 60 | 1 (NVD) |
| 22      | Yun          | 28  | IC    | USO + PALND     | SCC       | Yes                    | CDDP + ETP (3)        | NED    | 18 | NA |
| 23      | Koc          | 35  | IA    | LSO             | SCC       | Yes                    | PTX + CDDP (3)        | NED    | 96 | NA |
| 24      |              | 35  | IA    | LSO             | SCC       | -                      | -                     | NED    | 114 | NA |
| 25      |              | 35  | IA    | LSO + PLND + PALND + OM + App | SCC | - | - | NED | 96 | NA |

Abbreviations: RSO: right salpingo-oophorectomy, App: appendectomy, USO: unilateral salpingo-oophorectomy, LSO: left salpingo-oophorectomy, OM: omentectomy, PLND: pelvic lymph node dissection, PALND: para-aortic lymph node dissection, SCC: squamous cell carcinoma, AC: adenocarcinoma, NA: not available, NED: no evidence of disease, DOD: died of disease, NVD: normal vaginal delivery, CS: cesarean section.
age with early-stage MT-MCT at childbearing age. We only report that the prognosis of patients with early-stage MT-MCT who underwent FSS may be not inferior to that of patients who received radical surgery. Accordingly, FSS for women with MT-MCT should be carefully selected based on comprehensive informed consent of the potential increased risk of recurrence. Further evidences regarding MT-MCT is required to safely suggest FSS for patients who wish to preserve fertility.

PATIENTS AND METHODS

Between January 1986 and December 2016, patients with MT-MCT were accumulated by the Tokai Ovarian Tumor Study Group (TOTSG), consisting of Nagoya University Hospital and 13 affiliated institutions cooperating under the central pathological review system. Patients with EOC, malignant germ cell tumors or borderline epithelial tumors were excluded.

We collected and analyzed data from the medical records and clinical follow-up visits, including age, FIGO stage (International Federation of Gynecology and Obstetrics: 1988), type of surgery, tumor histology, tumor marker, adjuvant chemotherapy, date of recurrence, date of operation, date of death or last follow-up and pregnancy outcome. Two patients were excluded from this analysis due to insufficient information regarding surgical procedure and lost to follow-up immediately after operation. Histological slides were reexamined by our central pathological review system with no knowledge of the patients’ data.

The surgical management plan for patients was determined by staging at initial surgery. In principle, complete radical surgery including total hysterectomy and bilateral salpingo-oophorectomy with peritoneal staging and lymphadenectomy was performed except for patients who wished to preserve fertility at the age of <45 years old or had difficulty in undergoing radical surgery due to complications. In this study, we defined both complete radical surgery as mentioned above and incomplete surgery including total hysterectomy and bilateral salpingo-oophorectomy, as radical surgery. FSS was fundamentally defined as unilateral oophorectomy or cystectomy with or without omentectomy, together with cytology of ascites and evaluation of any suspected metastasis, including lymph nodes and intraperitoneal dissemination by preoperative or postoperative CT scan.

In order to evaluate oncological outcome of early stage MT-MCT, patients with stage I-II MT-MCT were divided into three groups: group A, patients who underwent FSS with eligible criteria as shown below; group B, patients who were less than 45 years old and underwent radical surgery including total hysterectomy and bilateral salpingo-oophorectomy; group C, patients who were more than 46 years old at the initial surgery. Eligible patients for group A were: (1) under 45 years old at the time of the initial surgery, (2) those who strongly desired to retain fertility, (3) were informed of the pros and cons of FSS, and signed a consent form. Following initial treatment, all patients underwent a periodic follow-up, including an ultrasonographic scan and CT scan. The overall survival (OS) was determined by the duration between the date of initial surgery and the last date of follow-up or death due to any reason. Disease-free survival (DFS) was defined as the duration between the date of surgery and that of recurrence or the last follow-up. The clinicopathological features among groups were evaluated by Chi-square tests. Survival curves were drawn using the Kaplan-Meier method and compared with the Log-rank test. Univariate and multivariate analyses were performed with Cox’s proportional hazard model. A P-value of <0.05 was defined as significant.

ACKNOWLEDGMENTS

The authors sincerely thank Drs Y. Kinoshita (Ogaki Municipal Hospital), K. Sakakibara (Okazaki Municipal Hospital), A. Takeda (Gifu Prefectural Tajimi Hospital), O. Yamamuro (Japanese Red Cross Nagoya Second Hospital), K. Mizuno (Japanese Red Cross Nagoya first Hospital) and K. Matsuzawa (Anjyo Kosei Hospital) to collaborate with data collection.

CONFLICTS OF INTEREST

The authors declare no potential conflicts of interest.

REFERENCES

1. Zanetta G, Chiari S, Rota S, Bratina G, Maneo A, Torri V, Mangioni C. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol. 1997; 104: 1030-5.
2. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, Modesitt SC, Lu KH, Geisler JP, Higgins RV, Magtibay PM, Cohn DE, Powell MA, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002; 87: 1-7.
3. Kajiyama H, Shibata K, Mizuno M, Nawa A, Mizuno K, Matsuzawa K, Kawai M, Hosono S, Nagasaka T, Kikkawa F. Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2011; 122: 334-8. https://doi.org/10.1016/j.ygyno.2011.04.016.
4. Fruscio R, Corso S, Ceppi L, Garavaglia D, Garbi A, Florian I, Franchi D, Cantu MG, Bonazzi CM, Milan R, Mangioni C, Colombo N. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol. 2013; 24: 138-44. https://doi.org/10.1093/annonc/mds241.
5. Song T, Choi CH, Park HS, Kim MK, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG. Fertility-sparing surgery for borderline ovarian tumors: oncologic safety and reproductive outcomes. Int J Gynecol Cancer. 2011; 21: 640-6. https://doi.org/10.1097/IGC.0b013e3182129842.

6. Di Tucci C, Casorrelli A, Morrocchi E, Palaia I, Muzzi L, Panici PB. Fertility management for malignant ovarian germ cell tumors patients. Crit Rev Oncol Hematol. 2017; 120: 34-42. https://doi.org/10.1016/j.critrevonc.2017.10.005.

7. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005; 18: S61-79. https://doi.org/10.1038/modpathol.3800310.

8. Ribeiro G, Hughesdon P, Wiltshaw E. Squamous carcinoma arising in dermoid cysts and associated with hypercalcemia: a clinicopathologic study of six cases. Gynecol Oncol. 1988; 29: 222-30.

9. Hackethal A, Brueggmann D, Bohlmann MK, Franke FE, Tinneberg HR, Munstedt K. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. Lancet Oncol. 2008; 9: 1173-80. https://doi.org/10.1016/S1470-2045(08)70306-1.

10. Ozgur T, Atik E, Silifele DB, Toprak S. Mature cystic teratomas in our series with review of the literature and retrospective analysis. Arch Gynecol Obstet. 2012; 285: 1099-101. https://doi.org/10.1007/s00404-011-2171-8.

11. Peterson WF. Malignant degeneration of benign cystic teratomas of the ovary: a collective review of the literature. Obstet Gynecol Surv. 1957; 12: 793-830.

12. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Malignant transformation of mature cystic teratoma of the ovary: experience at a single institution. Eur J Obstet Gynecol Reprod Biol. 2008; 141: 173-8. https://doi.org/10.1016/j.ejogrb.2008.07.032.

13. Karateke A, Gurbuz A, Kir G, Hailioglu B, Kabaca C, Devranoglu B, Yakut Y. Mucoepidermoid variant of adenosquamous carcinoma arising in ovarian dermoid cyst: a case report and review of the literature. Int J Gynecol Cancer. 2006; 16: 379-84. https://doi.org/10.1016/j.ijgyncancer.2006.02.023.

14. Curling OM, Potsides PN, Hudson CN. Malignant change in benign cystic teratoma of the ovary. Br J Obstet Gynaecol. 1979; 86: 399-402.

15. Tseng CJ, Chou HH, Huang KG, Chang TC, Liang CC, Lai CH, Soong YK, Hsueh S, Pao CC. Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Gynecol Oncol. 1996; 63: 364-70. https://doi.org/10.1006/gyno.1996.0337.

16. Rim SY, Kim SM, Choi HS. Malignant transformation of ovarian mature cystic teratoma. Int J Gynecol Cancer. 2006; 16: 140-4. https://doi.org/10.1016/j.ijgynecolcancer.2006.02.085.

17. Arioz DT, Tokyol C, Sahin FK, Koker G, Yilmaz S, Yilmazer M, Ozalp S. Squamous cell carcinoma arising in a mature cystic teratoma of the ovary in young patient with elevated carbohydrate antigen 19-9. Eur J Gynaecol Oncol. 2008; 29: 282-4.

18. Gainford MD, Tinker A, Carter J, Petru E, Nicklin J, Quinn M, Hammond I, Elit L, Lenhard M, Friedlander M. Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. Int J Gynecol Cancer. 2010; 20: 75-81. https://doi.org/10.1111/j.1525-1438.2008.01378.x.

19. Sakuma M, Otsuki T, Yoshinaga K, Utsunomiya H, Nagase S, Takano T, Niikura H, Ito K, Otomo K, Tase T, Watanabe Y, Yaegashi N. Malignant transformation arising from mature cystic teratoma of the ovary: a retrospective study of 20 cases. Int J Gynecol Cancer. 2010; 20: 766-71.

20. Budiman HD, Burges A, Ruhl IM, Friese K, Hasbargen U. Squamous cell carcinoma arising in a dermoid cyst of the ovary in pregnancy. Arch Gynecol Obstet. 2010; 281: 535-7. https://doi.org/10.1007/s00404-009-1193-y.

21. Chiang AJ, La V, Peng J, Yu KJ, Teng NN. Squamous cell carcinoma arising from mature cystic teratoma of the ovary. Int J Gynecol Cancer. 2011; 21: 466-74. https://doi.org/10.1097/IGC.0b013e31820d3e5b.

22. Yun NR, Park JW, Hyun MK, Park JH, Choi SJ, Song E. Squamous cell carcinoma arising in an ovarian mature cystic teratoma complicating pregnancy. Obstet Gynecol Sci. 2013; 56: 121-5. https://doi.org/10.5468/OGS.2013.56.2.121.

23. Koc S, Tapisiz OL, Turan T, Ocalan R, Ozfutu A, Boran N, Kose MF, Tulunay HG. Malignant transformation of mature cystic teratoma of the ovary: a case series. J Exp Ther Oncol. 2015; 11: 11-6.

24. Chiang AJ, Chen DR, Cheng JT, Chang TH. Detection of human papillomavirus in squamous cell carcinoma arising from dermoid cysts. Taiwan J Obstet Gynecol. 2015; 54: 559-66. https://doi.org/10.1016/j.tjog.2015.08.008.

25. Kajiyama H, Shibata K, Mizuno M, Hosono S, Kawai M, Nagasaka T, Kikkawa F. Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible? Hum Reprod. 2011; 26: 3297-302. https://doi.org/10.1093/humrep/der342.

26. Kikkawa F, Nawa A, Tamakoshi K, Ishikawa H, Kuzuuya K, Suganuma N, Hattori S, Furui K, Kawai M, Arii Y. Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary. Cancer. 1998; 82: 2249-55. https://doi.org/10.1002/(SICI)1097-0468(199806)82:4<2249::AID-CNCR1>3.0.CO;2-O.

27. Kajiyama H, Shibata K, Suzuki S, Ino K, Yamamoto E, Mizuno K, Sakakibara K, Matsuzawa K, Takeda A, Kinoshita Y, Kawai M, Nagasaka T, Nawa A, et al. Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary? Gynecol Oncol. 2008; 111: 523-6. https://doi.org/10.1016/j.ygyno.2008.04.001.
28. Bentivegna E, Fruscio R, Roussin S, Ceppi L, Satoh T, Kajiyama H, Uzan C, Colombo N, Gouy S, Morice P. Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients. Fertil Steril. 2015; 104: 1319-24. https://doi.org/10.1016/j.fertnstert.2015.06.008.